<DOC>
	<DOCNO>NCT00040404</DOCNO>
	<brief_summary>The purpose study establish safety CEP-1347 determine efficacious dose treatment Parkinson 's disease .</brief_summary>
	<brief_title>Safety Efficacy Study CEP-1347 Treatment Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients include study follow criterion meet : Willing able give inform consent Age 30 year old time diagnosis Parkinson 's disease Have idiopathic Parkinson 's disease least 2 cardinal sign disease : resting tremor , bradykinesia , rigidity Modified Hoehn Yahr stage less equal 2.5 Must screening procedure cancer appropriate patient 's age gender , within last 12 month ; willing obtain screening randomization Women : breastfeed Women : nonchildbearing potential ( ie , postmenopausal surgically sterile ) must use medically accepted contraceptive regimen least 60 day baseline visit , agree continue use throughout duration study 30 day final dose study drug . Women must give pregnancy test unless least 2 year postmenopausal surgically sterile . Patients exclude participate study 1 follow criterion meet : Have atypical Parkinsonism due drug , metabolic disorder , encephalitis , neurodegenerative disease Have confirm diagnosis Parkinson 's disease 5 year Have tremor score 3 body part Have know medical psychiatric condition may compromise participation study Have history prior malignancy ( exclude basal squamous cell cancer skin ) within previous 5 year Have unresolved abnormal cancer screen test result randomization Have great trace amount glycosuria screening , except know diabetic patient Have estimate creatinine clearance le 50 mL/min Have liver function test ( LFT ) great 3 time upper limit normal ( ULN ) Have clinically significant ECG laboratory find Have history malignant melanoma Have history seizure ( except febrile ) posttraumatic epilepsy Have MiniMental State Exam ( MMSE ) score ≤ 26 Have take another investigational drug within 60 day baseline visit Have receive prior treatment CEP1347 Have receive treatment agent potentially confound antiParkinson 's disease effect , specify substrate CYP3A4/5 , inhibitor CYP3A4/5 Received treatment within 6 month baseline visit agent may induce Parkinson 's disease Are expect , within next 3 month , reach level disability sufficient require dopaminergic therapy Have BECK depression score ≥ 15 Have know suspect sensitivity investigational study drug , include BCIT</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Idiopathic Parkinson 's disease</keyword>
	<keyword>Idiopathic Parkinson disease</keyword>
	<keyword>Parkinson 's disease , idiopathic</keyword>
</DOC>